VNRX

VolitionRX Ltd

0.2099

Nov 03 • 6:58 AM ET -0.0002 (-0.10%)

Healthcare Medical Devices USA Nano AMEX

Peers: AIDX BIAF LUCD MDXH GH FRNM BDSX PRPO XGN OPK

Index	-
Market Cap	5.85M
Enterprise Value	13.10M
Income	-26.10M
Sales	2.46M
Book/sh	-2.67
Cash/sh	0.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	75
IPO	Apr 25, 2007

P/E	-
Forward P/E	-
PEG	-
P/S	2.38
P/B	-
P/C	2.10
P/FCF	-
EV/EBITDA	-
EV/Sales	5.33
Quick Ratio	0.30
Current Ratio	0.30
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-3.84
EPS next Y	-0.73
EPS next Q	-0.38
EPS this Y	55.97%
EPS next Y	62.15%
EPS next 5Y	57.20%
EPS past 3/5Y	26.33% 13.42%
Sales past 3/5Y	77.98% 164.15%
EPS Y/Y TTM	21.31%
Sales Y/Y TTM	86.32%
EPS Q/Q	30.54%
Sales Q/Q	-1.97%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-49.78% -4.00%

Insider Own	4.77%
Insider Trans	0.00%
Inst Own	7.25%
Inst Trans	1.02%
ROA	-306.96%
ROE	-
ROIC	-
Gross Margin	53.07%
Oper. Margin	-790.23%
Profit Margin	-1061.82%
SMA20	10.27%
SMA50	-20.02%
SMA200	-90.05%
Trades

Shs Outstand	27.90M
Shs Float	26.57M
Short Float	4.31%
Short Ratio	0.13
Short Interest	1.15M
52W High	9.50 -97.79%
52W Low	0.16 34.21%
Volatility	14.19% 9.27%
ATR (14)	0.02
RSI (14)	45.07
Beta	1.14
Rel Volume	0.00
Avg Volume	8.59M
Volume	1,962

Perf Week	13.46%
Perf Month	-9.53%
Perf Quarter	-73.60%
Perf Half Y	-90.99%
Perf YTD	-95.89%
Perf Year	-97.60%
Perf 3Y	-98.70%
Perf 5Y	-99.71%
Perf 10Y	-99.73%
Recom	1.67
Target Price	8.04
Prev Close	0.21
Price	0.21
Change %	-0.10%

Consensus

Buy

Avg. Price Target

$8.04

Implied Upside

+3,730.4%

Analysts5incl. previous ratings

Rating Distribution4 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 08, 2025	Initiated	HH.C. Wainwright	Buy	$2.50	+1,091.0%
Feb 01, 2023	Downgrade	TThe Benchmark Company	Buy → Hold
Feb 17, 2022	Resumed	CCantor Fitzgerald	Overweight	$8 → $7	+3,234.9%
Mar 10, 2021	Initiated	CCantor Fitzgerald	Overweight	$8	+3,711.3%
May 16, 2018	Initiated	MMaxim Group	Buy	$6	+2,758.5%
May 14, 2018	Reiterated	TThe Benchmark Company	Buy	$7 → $5	+2,282.1%
Sep 07, 2016	Reiterated	RRodman & Renshaw	Buy	$12 → $10	+4,664.2%
Feb 01, 2016	Initiated	RRodman & Renshaw	Buy	$12	+5,617.0%

Oct-27-26 08:47AM	VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide (PR Newswire)
08:17AM	VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash (PR Newswire)
Sep-17-26 09:17AM	VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France (PR Newswire)
08:17AM	VolitionRx Participates in Launch of DETECSEPS Program in France (PR Newswire)
Sep-14-26 08:17AM	VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 (PR Newswire)
08:17AM	Loading…
Sep-10-26 08:17AM	Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference (PR Newswire)
Aug-26-26 09:17AM	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets (PR Newswire) -11.80%
08:17AM	Volition Announces Landmark Clinical Validation of Nu.Q NETs Biomarker in Sepsis (PR Newswire)
Aug-13-26 05:32PM	VolitionRX: Q2 Earnings Snapshot (Associated Press) -5.68% -14.78%
04:10PM	VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update (PR Newswire)
09:24AM	Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside (GuruFocus.com)
Aug-12-26 08:17AM	Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients (PR Newswire) -6.52%
Aug-11-26 04:10PM	VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update (PR Newswire) -6.75%
Aug-05-26 08:17AM	Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq Liquid Biopsy Technology (PR Newswire)
Jul-30-26 08:17AM	Volition Advances Nu.Q NETs Platform Towards Commercialization (PR Newswire)
08:17AM	Loading…
Jul-07-26 08:17AM	VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q Cancer Test (PR Newswire)
Jun-17-26 08:15AM	VolitionRx Announces Collaboration with Sysmex (PR Newswire)
Jun-07-26 06:30PM	VolitionRx Announces Pricing of $4.6 Million Public Offering (PR Newswire)
Jun-03-26 08:12AM	VolitionRx Files New Patent Protecting its Nu.Q NETs Test for Ebola Triage and Treatment Monitoring (PR Newswire) -10.34%
May-27-26 08:17AM	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets (PR Newswire)
May-15-26 07:02PM	VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) -9.09% +14.00%
May-14-26 06:32PM	VolitionRX: Q1 Earnings Snapshot (Associated Press) -6.78%
04:10PM	VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update (PR Newswire)
May-11-26 08:19AM	VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update (PR Newswire) -8.89%
May-06-26 08:17AM	VolitionRx Announces Submission of Manuscript for Nu.Q Vet Cancer Test in Cats (PR Newswire) +6.87%
Apr-29-26 08:17AM	Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing (PR Newswire) -5.04%
Apr-23-26 08:12AM	VolitionRx Announces Acceptance of Compliance Plan by NYSE American (PR Newswire) -8.69%
Apr-20-26 07:30AM	Volition Launches rNuQ Webshop Broadening Product Range (PR Newswire) -8.72%
Apr-02-26 09:01PM	VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -14.25%
Mar-31-26 06:51PM	VolitionRX: Q4 Earnings Snapshot (Associated Press) +6.32%
04:05PM	Loading…
04:05PM	VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update (PR Newswire)
09:18AM	VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
08:16AM	VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium (PR Newswire)
Mar-30-26 08:13AM	Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients (PR Newswire)
Mar-26-26 08:17AM	Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference (PR Newswire)
Mar-25-26 04:12PM	VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update (PR Newswire)
08:17AM	Volition Announces Detection of Over 95% of Early-Stage Cancers (PR Newswire)
Mar-18-26 08:17AM	Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA (PR Newswire) +5.26%
Mar-07-26 08:18AM	VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems (TipRanks)
Mar-06-26 08:10AM	Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems (PR Newswire)
Feb-25-26 08:10AM	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution (PR Newswire) +25.62%
Feb-10-26 08:07AM	Volition Announces the Appointment of New Distributor for Nu.Q Discover (PR Newswire)
Feb-09-26 05:20PM	VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (PR Newswire)
Feb-04-26 08:45AM	Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation (PR Newswire)
Jan-30-26 08:50AM	VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q Cancer Assays (PR Newswire) +13.50%
Jan-27-26 08:00AM	Volition Announces Data to Support Use of Nu.Q NETs in New Indication (PR Newswire)
Jan-20-26 08:25AM	Volition Continues to Extend Access to Nu.Q Vet Cancer Test (PR Newswire) +8.42%
Jan-16-26 08:45AM	Volition Sponsors Symposium at Veterinary Meeting and Expo (PR Newswire)
Jan-08-26 09:15AM	VolitionRx Secures $2.0 Million in Funding (PR Newswire) +24.19%
08:45AM	VolitionRx Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats (PR Newswire)
Dec-17-25 08:45AM	Volition Issues Business Review 2025 (PR Newswire) +10.33%
Dec-11-25 09:00AM	Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment (PR Newswire)
Dec-08-25 09:00AM	Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer (PR Newswire)
Dec-04-25 09:00AM	VolitionRx Limited Announces Inclusion of its Nu.Q NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis (PR Newswire) +9.49%
Nov-25-25 08:45AM	VolitionRx Limited Announces the First Sale of the Nu.Q Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use (PR Newswire) -9.97%
Nov-14-25 04:01PM	VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ... (GuruFocus.com) -6.60%
Nov-13-25 05:41PM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update (PR Newswire)
07:30AM	VolitionRX Ltd (VNRX) Q3 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-10-25 08:45AM	VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
Oct-17-25 08:00AM	Volition Donates Nu.Q Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs (PR Newswire)
Oct-10-25 08:30AM	VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants (PR Newswire) -22.65%
Oct-09-25 04:05PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants (PR Newswire) -7.41%
Oct-02-25 08:45AM	Volition Sponsors Upcoming GenomeWeb Webinar (PR Newswire)
Sep-29-25 09:30AM	Volition Signs Co-Marketing and Services Agreement with Hologic (PR Newswire)
Sep-09-25 08:45AM	Volition Signs First Human Out Licensing Deal (PR Newswire)
Aug-16-25 03:03AM	VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ... (GuruFocus.com)
Aug-14-25 05:06PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance) +7.94%
04:10PM	VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update (PR Newswire)
09:28AM	VolitionRX Ltd (VNRX) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-08-25 08:30AM	VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
Aug-04-25 04:01PM	VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering (PR Newswire)
Jul-16-25 08:00AM	Nu.Q Discover Expands Global Adoption and Epigenetic Innovation (PR Newswire) +8.36%
Jul-08-25 08:00AM	Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes (PR Newswire)
Jun-12-25 08:30AM	Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure (PR Newswire) +5.97%
Jun-04-25 09:00PM	Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties (PR Newswire) +5.85%
May-19-25 08:30AM	VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats (PR Newswire)
May-17-25 03:02AM	VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones (GuruFocus.com)
May-15-25 06:12PM	VolitionRX: Q1 Earnings Snapshot (Associated Press Finance) -5.22%
05:37PM	VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update (PR Newswire)
09:22AM	VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-12-25 08:30AM	VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
May-07-25 08:30AM	VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q NETs test adoption (PR Newswire)
Apr-29-25 08:30AM	VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets (PR Newswire) +9.27%
Apr-01-25 03:03AM	VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances (GuruFocus.com) -9.03%
12:31AM	VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
Mar-31-25 04:05PM	VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update (PR Newswire)
Mar-28-25 08:00AM	Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 (PR Newswire)
Mar-27-25 08:30AM	Volition to Host Virtual Investor Event on Nu.Q Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 (PR Newswire)
Mar-26-25 08:00AM	VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering (PR Newswire) -6.87%
Mar-25-25 09:30AM	VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update (PR Newswire)
Mar-21-25 08:30AM	Volition's Nu.Q Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry (PR Newswire)
Mar-20-25 08:30AM	Volition Introduces Nu.Q Cancer Blood Test in New Industry Primer for Lung Cancer (PR Newswire)
Mar-17-25 08:30AM	Volition Proudly Sponsors the 44th ISICEM Congress (PR Newswire)
Mar-13-25 08:30AM	Volition Signs first ever Nu.Q Vet Cancer Test Automation Agreement with Fujifilm Vet Systems (PR Newswire)
Mar-11-25 08:30AM	Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q Lung Cancer Test (PR Newswire)
Mar-04-25 08:30AM	Volition's Nu.Q Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time (PR Newswire)
Feb-28-25 08:30AM	Volition Showcases Nu.Q Vet Cancer Test at the 97th WVC Annual Conference (PR Newswire)
Feb-06-25 08:30AM	Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis (PR Newswire) +6.08%
Feb-05-25 09:15AM	Volition to Host Virtual Investor Event on Nu.Q NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reynolds Cameron John	President and CEO	Nov 17 '25	Buy	0.35	20,000	7,000	2,554,847	Nov 17 01:12 PM

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

FounderMr. Cameron Reynolds MBA

Chief Operating OfficerDr. Gaetan Michel Ph.D.

CFO & TreasurerMr. Terig Hughes

Ph.D.Dr. Jacob Vincent Micallef MBA

Group General CounselMr. Nicholas Plummer

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNRX

VolitionRX Ltd

Upgrade your Finviz experience